BLRX
BioLineRx Ltd. [BLRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BLRX Stock Summary
Top 10 Correlated ETFs
BLRX
Top 10 Correlated Stocks
BLRX
In the News
BLRX Financial details
Company Rating
Neutral
Market Cap
57.46M
Income
-63.92M
Revenue
4.8M
Book val./share
0.18
Cash/share
0.59
Dividend
-
Dividend %
-
Employees
79
Optionable
No
Shortable
Yes
Earnings
22 May 2024
P/E
-1.8
Forward P/E
-
PEG
-0.11
P/S
-
P/B
7.26
P/C
1.12
P/FCF
-3.3
Quick Ratio
1.78
Current Ratio
1.96
Debt / Equity
0.78
LT Debt / Equity
0.5
-
-
EPS (TTM)
-1
EPS next Y
-
EPS next Q
-
EPS this Y
154.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-26.92%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
1.38%
Inst Trans
0.73%
ROA
-100%
ROE
-171%
ROC
-1.04%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.65-2.53
52W High
-
52W Low
-
RSI
30
Rel Volume
0.43
Avg Volume
418.11K
Volume
180.7K
Perf Week
-5.74%
Perf Month
-44.08%
Perf Quarter
-49.63%
Perf Half Y
-55.12%
-
-
-
-
Beta
0.927
-
-
Volatility
0.03%, 0.24%
Prev Close
3.08%
Price
0.6598
Change
3.09%
BLRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.07 | |
| Net income per share | -2.75 | -1.84 | -0.64 | -0.37 | -0.94 | |
| Operating cash flow per share | -2.32 | -1.38 | -0.53 | -0.51 | -0.35 | |
| Free cash flow per share | -2.33 | -1.38 | -0.54 | -0.51 | -0.36 | |
| Cash per share | 2.82 | 1.34 | 1.29 | 0.99 | 0.67 | |
| Book value per share | 3.42 | 1.31 | 1.54 | 0.99 | 0.21 | |
| Tangible book value per share | 1.18 | 0.02 | 1.05 | 0.56 | -0.03 | |
| Share holders equity per share | 3.42 | 1.31 | 1.54 | 0.99 | 0.21 | |
| Interest debt per share | 1.26 | 0.54 | 0.13 | 0.28 | 0.19 | |
| Market cap | 21.96M | 42.48M | 90.16M | 30.44M | 100.83M | |
| Enterprise value | 27.12M | 33.33M | 81.82M | 32.18M | 108.17M | |
| P/E ratio | -0.82 | -1.37 | -3.2 | -1.61 | -1.66 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 21.01 | |
| POCF ratio | -0.97 | -1.83 | -3.82 | -1.16 | -4.46 | |
| PFCF ratio | -0.97 | -1.83 | -3.81 | -1.15 | -4.4 | |
| P/B Ratio | 0.66 | 1.93 | 1.32 | 0.6 | 7.63 | |
| PTB ratio | 0.66 | 1.93 | 1.32 | 0.6 | 7.63 | |
| EV to sales | 0 | 0 | 0 | 0 | 22.54 | |
| Enterprise value over EBITDA | -1.01 | -1.49 | -3.49 | -1.45 | -2.6 | |
| EV to operating cash flow | -1.2 | -1.44 | -3.47 | -1.23 | -4.78 | |
| EV to free cash flow | -1.19 | -1.44 | -3.46 | -1.21 | -4.72 | |
| Earnings yield | -1.22 | -0.73 | -0.31 | -0.62 | -0.6 | |
| Free cash flow yield | -1.04 | -0.55 | -0.26 | -0.87 | -0.23 | |
| Debt to equity | 0.31 | 0.35 | 0.07 | 0.24 | 0.78 | |
| Debt to assets | 0.2 | 0.16 | 0.06 | 0.16 | 0.16 | |
| Net debt to EBITDA | -0.19 | 0.41 | 0.36 | -0.08 | -0.18 | |
| Current ratio | 2.36 | 2.15 | 5.91 | 4.87 | 1.53 | |
| Interest coverage | -15.37 | -15.6 | -25.18 | -13.51 | -20.05 | |
| Income quality | 0.89 | 0.77 | 0.87 | 1.05 | 0.37 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 3.47 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 2.49 | |
| Intangibles to total assets | 0.41 | 0.46 | 0.27 | 0.29 | 0.23 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -0.06 | |
| Capex to depreciation | -0.08 | 0 | -0.14 | -0.48 | -0.21 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.48 | |
| Graham number | 14.54 | 7.35 | 4.7 | 2.85 | 2.09 | |
| ROIC | -0.65 | -0.75 | -0.35 | -0.34 | -1.73 | |
| Return on tangible assets | -0.85 | -1.21 | -0.47 | -0.35 | -1.24 | |
| Graham Net | 0.8 | -0.15 | 0.99 | 0.11 | -0.1 | |
| Working capital | 16.24M | 12.24M | 47.69M | 41.32M | 16.33M | |
| Tangible asset value | 11.49M | 316K | 46.38M | 28.96M | -1.63M | |
| Net current asset value | 8.02M | -2.38M | 44.1M | 26.46M | -3.52M | |
| Invested capital | 0.31 | 0.35 | 0.07 | 0.24 | 0.78 | |
| Average receivables | 976K | 377K | 141.5K | 431.5K | 714.5K | |
| Average payables | 6.14M | 6.86M | 5.74M | 6.27M | 8.92M | |
| Average inventory | 0 | 0 | 0 | -20.61M | -19.63M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 53.84 | |
| Days payables outstanding | 3.03K | 2.31K | 2.89K | 3.89K | 857.58 | |
| Days of inventory on hand | 0 | 0 | 0 | -23K | 154.1 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 6.78 | |
| Payables turnover | 0.12 | 0.16 | 0.13 | 0.09 | 0.43 | |
| Inventory turnover | 0 | 0 | 0 | -0.02 | 2.37 | |
| ROE | -0.8 | -1.4 | -0.41 | -0.37 | -4.58 | |
| Capex per share | -0.01 | 0 | 0 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.07 | |
| Net income per share | -0.05 | -0.25 | -0.3 | -0.26 | -0.19 | |
| Operating cash flow per share | -0.09 | -0.13 | -0.16 | -0.16 | 0.07 | |
| Free cash flow per share | -0.1 | -0.13 | -0.16 | -0.16 | 0.07 | |
| Cash per share | 0.83 | 0.7 | 0.53 | 0.42 | 0.59 | |
| Book value per share | 0.83 | 0.64 | 0.34 | 0.21 | 0.18 | |
| Tangible book value per share | 0.47 | 0.28 | -0.02 | 0.21 | -0.02 | |
| Share holders equity per share | 0.83 | 0.64 | 0.34 | 0.21 | 0.18 | |
| Interest debt per share | 0.22 | 0.22 | 0.24 | 0.23 | 0.13 | |
| Market cap | 36.3M | 54.76M | 98.45M | 112.73M | 113.73M | |
| Enterprise value | 38.04M | 58.58M | 101.88M | 118.31M | 121.07M | |
| P/E ratio | -2.96 | -0.89 | -1.33 | -1.76 | -2.05 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 23.69 | |
| POCF ratio | -6.39 | -6.83 | -10.17 | -11.39 | 22.79 | |
| PFCF ratio | -6.14 | -6.72 | -10.04 | -11.35 | 22.87 | |
| P/B Ratio | 0.71 | 1.4 | 4.68 | 8.58 | 8.6 | |
| PTB ratio | 0.71 | 1.4 | 4.68 | 8.58 | 8.6 | |
| EV to sales | 0 | 0 | 0 | 0 | 25.22 | |
| Enterprise value over EBITDA | -8.29 | -5.34 | -5.99 | -7.91 | -10.85 | |
| EV to operating cash flow | -6.69 | -7.31 | -10.52 | -11.95 | 24.26 | |
| EV to free cash flow | -6.44 | -7.19 | -10.39 | -11.92 | 24.34 | |
| Earnings yield | -0.08 | -0.28 | -0.19 | -0.14 | -0.12 | |
| Free cash flow yield | -0.16 | -0.15 | -0.1 | -0.09 | 0.04 | |
| Debt to equity | 0.24 | 0.33 | 0.64 | 1.01 | 0.78 | |
| Debt to assets | 0.16 | 0.19 | 0.23 | 0.25 | 0.16 | |
| Net debt to EBITDA | -0.38 | -0.35 | -0.2 | -0.37 | -0.66 | |
| Current ratio | 4.87 | 3.68 | 2.79 | 1.96 | 1.53 | |
| Interest coverage | -8.8 | -9.55 | -7.42 | -14.76 | 12.4 | |
| Income quality | 0.99 | 0.66 | 0.52 | 0.62 | -0.36 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 2.61 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0.65 | |
| Intangibles to total assets | 0.29 | 0.32 | 0.37 | 0.42 | 0.23 | |
| Capex to operating cash flow | 0.04 | 0.02 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.22 | -0.5 | -0.62 | -0.12 | -0.03 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.19 | |
| Graham number | 0.96 | 1.9 | 1.52 | 1.11 | 0.89 | |
| ROIC | -0.07 | -0.21 | -0.18 | -0.37 | -0.48 | |
| Return on tangible assets | -0.06 | -0.33 | -0.5 | -0.52 | -0.28 | |
| Graham Net | 0.09 | 0.23 | -0.08 | -0.21 | -0.09 | |
| Working capital | 41.32M | 32.29M | 22.25M | 14.08M | 16.33M | |
| Tangible asset value | 28.96M | 17.15M | -959K | -8.89M | -1.63M | |
| Net current asset value | 26.46M | 14.8M | -3.19M | -10.92M | -3.52M | |
| Invested capital | 0.24 | 0.33 | 0.64 | 1.01 | 0.78 | |
| Average receivables | 432K | 511.5K | 215K | 221.5K | 511.5K | |
| Average payables | 6.4M | 7.05M | 6.93M | 7.59M | 9.65M | |
| Average inventory | -20.61M | -20.61M | 0 | 676K | 1.65M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 13.28 | |
| Days payables outstanding | 3.35K | 2.48K | 3.06K | 3.44K | 264.95 | |
| Days of inventory on hand | -19.84K | 0 | 0 | 550.59 | 47.61 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 6.78 | |
| Payables turnover | 0.03 | 0.04 | 0.03 | 0.03 | 0.34 | |
| Inventory turnover | 0 | 0 | 0 | 0.16 | 1.89 | |
| ROE | -0.06 | -0.4 | -0.88 | -1.22 | -1.05 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
BLRX Frequently Asked Questions
What is BioLineRx Ltd. stock symbol ?
BioLineRx Ltd. is a IL stock and trading under the symbol BLRX
What is BioLineRx Ltd. stock quote today ?
BioLineRx Ltd. stock price is $0.6598 today.
Is BioLineRx Ltd. stock public?
Yes, BioLineRx Ltd. is a publicly traded company.
Company Profile
- Volume Average 418.11K
- Market Capitalization 57.46M
- Employee 79
- CEO Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
- Headquarters Hevel Modi'in,IL
- IPO Date 2011-07-27
-
Website
https://www.biolinerx.com 
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
